甲状腺癌靶向治疗进展

Progress of Molecular Targeted Therapy for Thyroid Cancer

目的总结近年来有关甲状腺癌的分子靶向治疗药物的研发及进展。方法通过Medline及CHKD期刊全文数据库,查找甲状腺癌的分子病因学、靶向药物作用机理及药效评估的国内外相关文献。结果目前已有4种靶向药物(索拉非尼、乐伐替尼、凡德尼布和卡博替尼)经FDA批准用于治疗晚期甲状腺癌,其主要可明显延长患者的无进展生存期。另外,目前已有多个新的靶向药物完成了Ⅰ期或Ⅱ期临床试验,有可能在未来成为治疗晚期甲状腺癌新的选择。结论分子靶向药物已成为晚期甲状腺癌的主要治疗手段,但仍需研发更有效的新药和探讨联合用药的方案以提高疗效。

Objective To review the recent progress of the molecular targeted therapy for thyroid cancer. Methods The literatures of molecular etiology for thyroid cancer, mechanism and evaluation of targeted therapy via Medline and CHKD database were reviewed. Results So far, four molecular targeted drugs （Sorafenib, Lenvatinib, Vandetanib, and Cabozantinib） have been approved for treatment of advanced thyroid cancer by FDA. They can mainly improve the patient＇s progression-free survival. Besides, several new molecular targeted drugs have accomplished Ⅰ phase or Ⅱphase clinical trials. These drugs may be new options for treatment of advanced thyroid cancer in the future. Conclusions Molecular targeted drugs have been the main therapeutic method for advanced thyroid cancer. However, we should invent more effective new drugs and investigate the drug combination to improve the therapeutic effect.